Sandoz Announces New Phase I Data On Proposed Biosimilar Pegfilgrastim

Shutterstock photo

(RTTNews.com) - Sandoz, a division of Novartis ( NVS ), announced data demonstrating the pharmacokinetics or PK, pharmacodynamics or PD, safety and immunogenicity of proposed biosimilar pegfilgrastim as compared to the reference biologic, Neulasta.

The Phase I study, conducted in healthy volunteers, confirmed that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of PK, PD, safety and immunogenicity profiles.

Sandoz biosimilar pegfilgrastim is currently under review by the European Medicines Agency for use in the same indication as the reference biologic. Pegfilgrastim is a long-acting formulation of filgrastim (granulocyte colony-stimulating factor [G-CSF]).


This article appears in: Stocks , Politics
Referenced Symbols: NVS

More from RTT News


See headlines for NVS

Research Brokers before you trade

Want to trade FX?